ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

2024.02.18
At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition, ESMO 2023 also reported TAR201 and EV-302 study. Dr. Andrea Nccchi shared his views on these latest studies in an interview with " Oncology Frontier ".
ESMO Highlights | Professor WeiYu’s Commentary on Advances in Neoadjuvant Therapy and Bladder Preservation in Bladder Cancer

ESMO Highlights | Professor WeiYu’s Commentary on Advances in Neoadjuvant Therapy and Bladder Preservation in Bladder Cancer

2023.11.17
 Bladder cancer is a common tumor in the urinary system, with muscle-invasive bladder cancer (MIBC) accounting for approximately 20% of all bladder cancers. Nearly half of non-muscle-invasive bladder cancer (NMIBC) patients may relapse into MIBC. Currently, various explorations in neoadjuvant therapy, including chemotherapy, immunotherapy, and their combination, have been conducted. The recent ESMO conference revealed several advancements in research. Professor Wei Yu from Peking University First Hospital shares the latest developments in neoadjuvant therapy and bladder preservation for bladder cancer.